ELV reaffirms 2026 EPS guidance; expects 12%+ EPS growth in 2027
Elevance management reaffirmed 2026 EPS guidance and expects at least 12% EPS growth in 2027. The company cited strong execution across Medicare Advantage, Medicaid and Carelon, with AI and targeted investments supporting productivity.
Management reaffirmed 2026 EPS guidance and said it expects at least 12% EPS growth in 2027, supported by execution across Medicare Advantage, Medicaid and Carelon. The company said AI and targeted investments are improving productivity, while disciplined capital deployment is expected to support long-term growth.